A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten
American Journal of Cardiovascular Drugs · 2024-11 · 24 (6) · 791-799
DOI: 10.1007/s40256-024-00672-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 21.08.2024. Verfasst von Zeynep Yukselen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA, USA. Hauptthemen laut MEDLINE: Pharmacovigilance, Adverse Drug Reaction Reporting Systems, United States Food and Drug Administration, Bayes Theorem. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA, USA.
- Division of Cardiology, Department of Internal Medicine, Lahey Hospital Medical Center, Burlington, MA, 01805, USA.
- Division of Cardiology, Department of Internal Medicine, Lahey Hospital Medical Center, Burlington, MA, 01805, USA. Sourbha.s.dani@lahey.org.
Zitieren
APA
Yukselen, Z., Raju, A. K. V., Kumar, P. A., Ujjawal, A., Dasari, M., Parajuli, S., Nakhla, M., Bansal, K., Ganatra, S., & Dani, S. S. (2024). A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten. American Journal of Cardiovascular Drugs, 24(6), 791-799. https://doi.org/10.1007/s40256-024-00672-2
Vancouver
Yukselen Z, Raju AKV, Kumar PA, Ujjawal A, Dasari M, Parajuli S, et al. A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten. American Journal of Cardiovascular Drugs. 2024;24(6):791-799. doi:10.1007/s40256-024-00672-2
BibTeX
@article{Yukselen2024,
author = {Yukselen, Zeynep and Raju, Arvind Kumar Venkataramana and Kumar, Pramukh Arun and Ujjawal, Aditi and Dasari, Mahati and Parajuli, Shreyash and Nakhla, Michael and Bansal, Kannu and Ganatra, Sarju and Dani, Sourbha S},
title = {A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten},
journal = {American Journal of Cardiovascular Drugs},
year = {2024},
volume = {24},
number = {6},
pages = {791--799},
doi = {10.1007/s40256-024-00672-2}
}
EUVIMED